Mélanome uvéal et tumeurs oculaires SALOME / IC 2019-13 Follow-up of patients with uveal melanoma adapted to the risk of relapse. Paris SOPHIE PIPERNO-NEUMANN
Sarcomes STRASS 2 - ETUDE 1809-STBSG A randomized phase III study of neoadjuvant chemotherapy;followed by surgery versus surgery alone for patients with;High Risk RetroPeritoneal Sarcoma (STRASS 2) Paris SYLVIE BONVALOT
Prostate TEMPOS (GETUG P14) Erectile Dysfunction in Good Prognosis Prostate Cancer: a Phase III Medico-economic Study Comparing Brachytherapy to Stereotactic Body Radiotherapy Paris, Saint-Cloud
Sein métastatique RH+ AMBRE OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE III STUDY, COMPARING;STANDARD CHEMOTHERAPY TO ENDOCRINE THERAPY + ABEMACICLIB;COMBINATION AS INITIAL METASTATIC TREATMENT AMONG PATIENTS WITH;VISCERAL METASTASIS OF ER+ HER2- BREAST CANCER, HIGH BURDEN;DISEASE Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD, FRANCOIS-CLEMENT BIDARD
Sein Néoadjuvant EMBER-2 (J2J-MC-JZLB) EMBER-2: A Phase 1, Open-Label, Preoperative Window Study Evaluating the Biological Effects of LY3484356 in Post-menopausal Women With Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Saint-Cloud FRANCOIS-CLEMENT BIDARD
Pédiatrie Tumeurs solides INFORM2 - NIVENT (IC 2018-07) INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies Paris GUDRUN SCHLEIERMACHER
Prostate PRESTO (GETUG-AFU 36) Prostate-cancer treatment using stereotactic radiotherapy for oligometastases;ablation in hormone-sensitive patients À a GETUG-AFU phase III randomized controlled trial Paris
Pédiatrie Tumeurs solides GSK213406 A Phase 1, Multicentre, Open-label, Dose-escalation and Cohort Expansion Study of;Niraparib and Dostarlimab in Paediatric Patients with Recurrent or Refractory Solid Tumours Paris FRANCOIS DOZ
Sein Néoadjuvant NEOVAB Prospective Multicenter Pilot Study to Evaluate the Accuracy of Percutaneous Biopsy by Vacuum-assisted Biopsy (VAB) to Assess Pathological Complete Response in Patients With Clinical and Radiological Complete Response After Neoadjuvant Chemotherapy (NeoVAB) Saint-Cloud
Pédiatrie Tumeurs solides iMATRIX-Alectinib (GO42286) A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available. Paris FRANCOIS DOZ